Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 3 February from 10am to 6pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:
1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Ray Armstrong Present for all notes
4. Dr Jeff Aronson Present for all notes
5. Professor John Cairns Present for all notes
6. Dr Rebecca Kearney Present for all notes
7. Dr Sanjay Kinra Present for all notes
8. Dr Miriam McCarthy Present for all notes
9. Professor Ruairidh Milne Present for all notes
10. Mr Christopher O'Regan Present for all notes
11. Professor Stephen Palmer Present for all notes
12. Professor John Pounsford Present for all notes
13. Dr Danielle Preedy Present for all notes
14. Dr Nigel De-Kare Silver Present for all notes
15. Dr Marta Soares Present for all notes
16. Professor Ken Stein Present for all notes
17. Dr Nicky Welton Present for all notes
18. Mr Nigel Westwood Present for all notes

In attendance:

Dr Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes

Dr Elisabeth George Associate Director, National Institute for Health and Care Excellence Present for notes 21 to 32

Mr Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Ms Marcia Miller Administrator, National Institute for Health and Care Excellence Present for all notes
Mr Richard Diaz  Technical Analyst, 
National Institute for 
Health and Care 
Excellence  Present for notes 1 to 20

Ms Raisa Sidhu  Technical Adviser, 
National Institute for 
Health and Clinical 
Excellence  Present for notes 1 to 20

Dr Rosie Lovett  Technical Adviser, 
National Institute for 
Health and Clinical 
Excellence  Present for notes 21 to 32

Dr Miriam Brazzelli  Senior Research Fellow, 
Aberdeen HTA Group  Present for notes 1 to 18
Dr Ewen Cummins  Health Economist, 
Aberdeen HTA Group  Present for notes 1 to 18
Professor Craig Ramsay  HCA Programme 
Director and Senior 
Statistician, Aberdeen 
HTA Group  Present for notes 1 to 18

Dr George Follows  Consultant 
Haematologist, 
Cambridge University 
Hospitals NHS 
Foundation Trust, 
nominated by the UK 
CLL Forum  Present for notes 7 to 16

Professor Peter Hillmen  Professor of 
experimental 
haematology, University 
of Leeds, nominated by 
Janssen  Present for notes 7 to 16
Ms Molly Fletcher  Patient expert, 
nominated by the CLL 
Support Association  Present for notes 7 to 16
Mr Nick York  Patient expert and 
Trustee of the CLL 
Support Association, 
nominated by the CLL 
Support Association  Present for notes 7 to 16

Dr Bram Ramaekers  Health Economist, 
Department of Clinical 
Epidemiology and 
Medical Technology 
Assessment, Maastricht 
University Medical  Present for notes 21 to 31

Non-public observers: 

Professor Nicky Britten  Professor of Applied 
Health Care Research, 
NIHR PenCLAHRC 
Theme Lead for Person  Present for notes 1 to 16
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ibrutinib for treating chronic lymphocytic leukaemia [ID749] and abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy [ID503].

2. The Chair welcomed Mr Nigel Westwood to his first meeting as a member of the Appraisal Committee.

3. The Chair welcomed Dr Sanjeev Patel to his first meeting as Vice-Chair of the Committee.

4. The Chair informed the Committee of the non-public observers at this meeting: Professor Nicky Britten, Ms Linda Grainger, Ms Chloe Kastoryano and Ms Pilar Pinilla-Dominguez.

5. Apologies were received from Mr Mark Chapman, Dr Neil Iosson, Ms Anne Joshua and Mr Alun Roebuck.

Any other Business

6. The Committee were given an update on issues and timings relating to other appraisals.

Notes from the last meeting

7. The minutes of the 6 January Committee meeting were approved.

Appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749]

Part 1 – Open session

8. The Chair welcomed the invited experts: Dr Miriam Brazzelli, Dr Ewen Cummins, Professor Craig Ramsay, Dr George Follows, Professor Peter Hillmen, Ms Molly Fletcher and Mr Nick York to the meeting and they introduced themselves to the Committee.

9. The Chair welcomed company representatives from Janssen to the meeting.

10. The Chair asked all Committee members to declare any relevant interests

    10.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam
McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.

11. The Chair asked all NICE Staff to declare any relevant interests.

11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.

12. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

12.1. Dr Miriam Brazzelli, Dr Ewen Cummins, Professor Craig Ramsay and Ms Molly Fletcher declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.

12.2. Dr George Follows declared a personal non-specific financial interest as he has sat on advisory boards, provided consultancy and paid lectures for companies including Janssen, Gilead, Abbvie, Roche, GSK, Celgene, Mundipharma, Napp, CTi therapeutics, Takeda and local Cambridge biotech companies. He also stated that he has attended conferences in the UK and overseas as a sponsored guest of companies including Janssen and Takeda. Dr Follows also stated that he has share holdings (all less than £5,000) in a number of pharmaceutical biotechnology companies, but none which manufacture or market a drug licensed to treat CLL.

12.2.1. It was agreed that these declarations would not prevent Dr Follows from participating in this section of the meeting.

12.3. Professor Peter Hillmen declared a personal non-specific financial interest as he has received honoraria and research support from Janssen and other pharmaceutical companies.

12.3.1. It was agreed that this declaration would not prevent Professor Hillmen from participating in this section of the meeting.

12.4. Mr Nick York declared a non-personal non-specific financial interest as he is a trustee of the CLL Support Association which receives unrestricted educational grants from several pharmaceutical companies.

12.4.1. It was agreed that this declaration would not prevent Mr York from participating in this section of the meeting.
13. The Chair introduced the lead team, Dr Ray Armstrong, Professor Ken Stein and Dr Dani Preedy who gave presentations on the clinical effectiveness and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia.

14. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

15. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

16. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

17. Discussion on confidential information continued. This information was supplied by the company.

18. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

19. The Committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia.

20. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy [ID503]**

**Part 1 – Open session**

21. The Chair welcomed the invited expert: Dr Bram Ramaekers to the meeting and he introduced himself to the Committee.

22. The Chair welcomed company representatives from Janssen to the meeting.

23. The Chair asked all Committee members to declare any relevant interests

23.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the
appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

24. The Chair asked all NICE Staff to declare any relevant interests.

24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

25. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

25.1. Dr Bram Ramaekers declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.

26. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

28. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

29. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

30. Discussion on confidential information continued. This information was supplied by the company.

31. The Chair then thanked the Evidence Review Group representative for his attendance, participation and contribution to the appraisal and he left the meeting.

32. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

33. Wednesday 2 March 2016 at Prospero House, 241 Borough High Street, London, SE1 1GA